PCRX Pacira Biosciences Inc.

Pacira to Report 2020 Financial Results on Thursday February 25, 2021

Pacira to Report 2020 Financial Results on Thursday February 25, 2021

PARSIPPANY, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2020 financial results before the open of the U.S. markets on Thursday, February 25, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

To participate in the conference call, dial 1-877-845-0779 and provide the passcode 4864607. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at .

For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 4864607. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .



Investor Contact:

Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
  
EN
18/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE

Pacira to Report First Quarter 2026 Financial Results on Thursday Apri...

Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026 BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter 2026 financial results after the close of the U.S. markets on Thursday April 30, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and ...

 PRESS RELEASE

Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Health...

Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures -- Select findings demonstrate that the use of EXPAREL® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods — -- Reduced opioid use observed at 6 months post-surgery among Medicare Advantage patients with low back pain in THA Study -- BRISBANE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioScience...

 PRESS RELEASE

Pacira BioSciences to Participate in Fireside Chat at the 25th Annual ...

Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on Wednesday, April 15, 2026. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s ...

 PRESS RELEASE

Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Redu...

Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting -- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from two real-world studies evaluating the economic benefit...

 PRESS RELEASE

Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation

Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation -- Issues Statement in Response to DOMA’s Nomination of Director Candidates --  -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three director candidates to stand for election to the Pacira Board of Directors (the “Board”)...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch